Barbara Soini
Ospedale Santa Chiara · 22 works · 362 citations · h-index 5
Top works
- Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
- Risk factors for thrombosis in patients with immune mediated heparin‐induced thrombocytopenia
- Autoimmune thrombocytopenia (AITP) and thyroid autoimmune disease (TAD): overlapping syndromes?
- Multiple Rechallenges for Castration-resistant Prostate Cancer Patients Responding to First-line Docetaxel: Assessment of Clinical Outcomes and Predictive Factors
- Clinical and laboratory factors that affect the post-transfusion platelet increment
- Weekly paclitaxel (wPCT) for pretreated patients (pts) with advanced non-small cell lung cancer (aNSCLC): Updated data from a single institution experience in the daily clinical practice.
- Increased endothelial and platelet soluble selectins in heparin-induced thrombocytopenia associated with thrombosis.
- Two Methods for Intraplatelet Serotonin Evaluation: Their Use in Thrombocytosis
- Essential thrombocythemia following polycythemia vera: an unusual sequence.
- Braf Mutation in Colon Cancer Patients with Microsatellite Instability (Msi): a Monoinstitutional Analysis
- Gemcitabine (G) and cisplatin (C) in a modified 3-week schedule for non-small cell lung cancer (NSCLC): Impact on hematologic toxicity and dose intensity (DI)
- Role of Ki67 labeling index (LI) in subdividing homogeneous ER-positive grading groups of early breast cancer (EBC) in distinct biologic entities.
- Adjuvant chemoradiotherapy in patients (pts) with resectable gastric (GC) or gastroesophageal junction cancer (GEJC): A monoinstitutional experience.
- Platelet Function in Alcoholics Treated with Disulfiram
- Real-time quality assessment of cancer care through information technology instruments incorporated into routine clinical practice
- Individual risk factors for venous thromboembolism (VTE) in cancer patients treated with targeted therapies (TT)
- Predictive factors of response to docetaxel (DOC) rechallenge (ReC) in castration-resistant prostate cancer (CRPC) patients (pts).
- Multiple rechallenges (ReCs) with docetaxel (DOC) as an option after first-line therapy in patients (pts) with castration-resistant prostate cancer (CRPC).
- Prognostic value of positron emission tomography (PET) in patients (pts) with metastatic or locally advanced cervical cancer (CC): A monoinstitutional experience.
- Paclitaxel, 5-fluorouracil, and cisplatin (PFC) combination in patients (pts) with localized or advanced gastric-gastroesophageal junction adenocarcinoma (G-GEJA): A monoistitutional experience.